Combinations of phosphoinositide 3-kinase inhibitor compounds chemotherapeutic agents, and methods of use

Patent Citations (20)

Non-Patent Literature (34)

• Nagata et al ‘PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patient’ Cancer Cell, vol. 6, p. 117-127, 2004.Examiner
• Bernhard, E.J., et al., “Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes”, Cancer Research, 58(8), 1754-1761 (1998).Applicant
• Bianco, R., et al., “Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors”, Oncogene, 22, 2812-2822 (2003).Applicant
• Briel, D., et al., “Selective nucleophilic replacement of the benzylsulfanyl group in 2,4-disulfanyl-substituted thieno[2,3-d]pyrimidin-6-carboxylic acid derivatives by secondary amines”, Journal of Heterocyclic Chemistry, 42(5), 841-846 (2005).Applicant
• “CellTiter-Glo® Luminescent Cell Viability Assay: instructions for use of products G7570, G7571, G7572 and G7573”, Promega Technical Bulletin TB288, Internet URL: www.promega.com, retrieved Sep. 18, 2009, 13 pages.Applicant
• Chou, T-C et al., “Quantitative Analysis of Dose-Effect Relationships: The Combined Effects of Multiple Drugs or Enzyme Inhibitors”, Adv. Enzyme Regul. (1984) 22:27-55.Applicant
• Edwards et al., “Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells”, Molecular Cancer Therapeutics, (2006), 5(3), 645-654.Applicant
• Fludzinski et al., “Indazoles as Indole Bioisosteres: Synthesis and Evaluation of the Tropanyl Ester and Amide of Indazole-3-carboxylate as Antagonists at the Serotonin 5HT3 Receptor”, Journal of Medicinal Chemistry, 30(9), p. 1535, 1987.Applicant
• Folkes et al., “The Identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer”, Journal of Medicinal Chemistry, (2008), 51(18), 5522-5532.Applicant
• Friedman et al., “Preclinical analysis of combined PI3K and MEK inhibition as a strategy for the treatment for cancer”, American Association for Cancer Research Annual Meeting, 2008, 99th:Apr. 14, Abstract LB-110.Applicant
• Friedman et al., “Anti-angiogenic effects of PI3K/Akt/mTOR pathway inhibitors”, EORTC, Oct. 2008, Poster 227.Applicant
• Hayakawa M., et al., “Synthesis and biological evaluation of pyrido[3′,2′:4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110alpha inhibitors”, Bioorganic & Medicinal Chemistry Letters, 17(9), 2438-2442 (2007).Applicant
• Heffron et al., “Evolution of Potent and Efficacious PI3 Kinase Inhibitors”, Abstracts of Papers, 237th ACS National Meeting, Salt Lake City, UT, United States, Mar. 22-26, (2009), MEDI-220.Applicant
• Ihle et al., “The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth facor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts”, Molecular Cancer Therapy, vol. 4, pp. 1349-1357, 2005.Applicant
• Kesari et al., “Targeted Molecular Therapy of Malignant Gliomas”, Current Oncology Reports, (2006), 8(1), 58-70.Applicant
• Lee-Hoeflich et al., “A Central Role for HER3 in HER2-Amplified Breast Cancer: Implications for Targeted Therapy”, Cancer Res., (2008), 68(14), 5878-87.Applicant
• Li, T., et al., “Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells”, Cancer Therapy: Preclinical, 13(11), 3413-3422 (2007).Applicant
• Loprevite, M., et al., “In vitro study of farnesyltransferase inhibitor SCH 66336, in combination with chemotherapy and radiation, in non-small cell lung cancer cell lines”, Oncology Reports, 11, 407-414 (2004).Applicant
• Mendoza, N., et al., “Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer”, Cancer Research, 62(19), 5485-5488 (2002).Applicant
• Morgensztern et al., “PI3K/Akt/mTOR pathway as a target for cancer therapy”, Anti-Cancer Drugs, (2005), 16(8), 797-803.Applicant
• Nielsen, L., et al., “Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 Adenovirus) in preclinical cancer models”, Cancer Research, 59(23), 5896-5901 (1999).Applicant
• Ohta et al., “Inhibition of Phosphatidylinositol 3-Kinase Increases Efficacy of Cisplatin in in Vivo Ovarian Cancer Models”, Endocrinology (2006), 147(4), 1761-1769.Applicant
• Pao et al., “KRAS Mutations and Primary Resistance of Lung Adenomacarcinomas to Gefitinib or Erlotinib”, PLoS Medicine, 2(1), pp. 57-61, 2005.Applicant
• Premkumar et al., “Synergistic Interaction Between 17-AAG and Phosphatidylinositol 3-Kinase Inhibition in Human Malignant Glioma Cells”, Molecular Carcinogenesis, (2006), 45(1), 47-59.Applicant
• Sampath et al., “Combination of class 1 PI3K inhibitor, GDC-0941, with standard of care therapeutics results in enhanced antitumour responses in human cancer models in vitro and in vivo”, EORTC, Oct. 2008, Poster 220.Applicant
• Samuels et al., “Inhibiting Phosphoinositide 3-Kinases”, Cancer Biology & Therapy (2005), 4(5), 546-547.Applicant
• Tumkevicius, S., et al., “First example of synthesis of thieno-[2,3-d]pyrimidine-6-carbaldehydes by oxidation of thieno[2,3-d]pyrimidin-6-yl methanols with molecular iodine”, Chemistry of Hetrocyclic Compounds, 41(6), 800-801 (2005).Applicant
• Wendel et al., “Determinants of Sensitivity and Resistance to Rapamycin-Chemotherapy Drug Combinations in vivo”, Cancer Research (2006), 66(15), 7639-7646.Applicant
• Yu et al., “PWT-458, A Novel Pegylated-17-Hydroxywortmannin, Inhibits Phosphatidylinositol 3-Kinase Signaling and Suppresses Growth of Solid Tumors”, Cancer Biology & Therapy, (2005), 4(5), 538-545.Applicant
• Yu, D. et al., “Role of erbB2 in breast cancer chemosensitivity”, BioEssays, 22(7), 673-680 (2000).Applicant
• Zhou, H., et al., “Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-Overexpressing breast cancer cell line proliferation, radiosensitization, and resistance”, Int. J. Radiation Oncology Biol. Phys., 58(2), 344-352, (2004).Applicant
• Ikezoe et al., “Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells”, Leuk. Res., vol. 31, 673-682 (2007).Applicant
• Janmaat et al., “Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositiol-3 kinase pathways in non-small cell lung cancer cells”, Int. J. Cancer, vol. 118, 209-214 (2006).Applicant
• Shingu et al., “Synergistic Augmentation of Antimicrotubule Agent-induced Cytotoxicity by a Phosphoinositide 3- Kinase Inhibitor in Human Malignant Glioma Cells”, Cancer Research 63, 4044-4047 (2003).Applicant